Dowlati, Afshin
Harvey, R. Donald
Carvajal, Richard D.
Hamid, Omid
Klempner, Samuel J.
Kauh, John Sae Wook
Peterson, Daniel A.
Yu, Danni
Chapman, Sonya C.
Szpurka, Anna M.
Carlsen, Michelle
Quinlan, Tonya
Wesolowski, Robert http://orcid.org/0000-0003-0606-0648
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 8 November 2020
Accepted: 10 February 2021
First Online: 23 February 2021
Declarations
:
: The study was performed in accordance with the International Conference on Harmonization guidelines and Declaration of Helsinki 1964 and its amendments. The Institutional review board of each study site approved the study protocol, information brochure and the informed consent form before study initiation.
: Informed consent was obtained from all individual participants included in the study.
: Patients provided informed consent to regarding publishing their data.
: <b>A. Dowlati</b> reports other from Glaxo Smith Kline, non-financial support from Glaxo Smith Kline; grants from EMD Serono, Tesaro, Roche, Vertex, Regeneron; grants and personal fees from Abbvie, Astra Zeneca, Millenium, Seattle Genetics; grants from Eli Lilly, Takeda, Ipsen, United Therapeutics, Mirati, Bristol Myers Squibb, Incuron; personal fees from Ariad, grants from Bayer.<b>RD. Harvey</b> has nothing to disclose.<b>R. Carvajal</b> reports personal fees and other from BMS, Incyte, Immunocore, Merck Roche/Genentech; personal fees from Castle Biosciences, Compugen, Foundation Medicine, I-Mab, PureTech, Sanofi Genzyme, Sorrento Therapeutics, Aura Biosciences, Chimeron, Rgenix; other from Amgen, Novartis, Pfizer, AstraZeneca, Bellicum, Plexxikon, Mirati, Macrogenics, Corvus, Bayer, Eli Lilly, Astellis, outside the submitted work.<b>O. Hamid</b> received personal fees from Aduro, Akeso, Amgen, Array, Beigene, BMS, Genentech, GSK, Immunocore, Incyte, Janssen, Merck, Nextcure, Novartis, Sanofi Regeneron, Seattle Genetics, Tempus, Zelluna, Array Pfizer, BMS, Novartis, Sanofi Regeneron; other from Arcus, Aduro, Akeso, Amgen, Array, BMS, CytomX, Exelixis, Genentech, GSK, Immunocore, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Sanofi Regeneron, Seattle Genetics, Torque, Zelluna.<b>SJ. Klempner</b> received personal fees from Eli Lilly, Merck, Bristol Myers Squibb, Foundation Medicine, Inc., Pieris; Stock/equity from Turning Point Therapeutics.<b>JSW. Kauh</b> is a former employee of Eli Lilly and Company and presently working at Hutchison MediPharma Inc.<b>R. Wesolowski</b> reports other (Lilly covered the cost of conducting this study at our institution).<b>AM. Szpurka, DA. Peterson, D. Yu, M. Carlsen, SC. Chapman, and T. Quinlan,</b> are employees and stockholder at Eli Lilly and Company.